---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000140"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:25:20.487144+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance

## Summary
- Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.
- GAAP net loss $143.5M ($3.11/sh) on $163.2M goodwill impairment; non-GAAP net income $38.2M.
- Adjusted EBITDA $54.7M; cash $453.8M. FY 2024 guidance reaffirmed ($680M-$705M rev).
- CMS final rule confirms separate NOPAIN reimbursement for EXPAREL/iovera° starting Jan 1, 2025; new J-code J0666 effective same date.
- Executive employment agreements amended for Gaugler, Slonin, Williams: enhanced severance (12-mo salary continuation; 18-mo on change of control).

## SEC filing metadata
- accession: 0001396814-24-000140
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000140/0001396814-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000140/pcrx-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000140
- JSON: https://secwatch.observer/filing/0001396814-24-000140.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.